Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Prostate Cancer

  Free Subscription


25.03.2024

2 AJR Am J Roentgenol
7 BJU Int
1 BMC Cancer
1 Br J Cancer
1 Cancer
1 Cancer Lett
1 Clin Cancer Res
1 Eur Radiol
10 Eur Urol
4 Int J Radiat Oncol Biol Phys
1 J Clin Oncol
1 J Urol
2 PLoS One
2 Prostate


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    AJR Am J Roentgenol

  1. DE OLIVEIRA CORREIA ET, Purysko AS, Paranhos BM, Shoag JE, et al
    Reply to "Prostate Cancer Screening and Prostate MRI: Hypotheses Founded on Uncertain Evidence".
    AJR Am J Roentgenol. 2024 Mar 20. doi: 10.2214/AJR.24.31168.
    PubMed        

  2. TAKAHASHI T
    Prostate Cancer Screening and Prostate MRI: Hypotheses Founded on Uncertain Evidence.
    AJR Am J Roentgenol. 2024 Mar 20. doi: 10.2214/AJR.24.31070.
    PubMed        


    BJU Int

  3. PARRY MG, Sujenthiran A, Nossiter J, Morris M, et al
    Reply to: Letter to the editor regarding the article 'Prostate cancer outcomes following whole-gland and focal high-intensity focused ultrasound'.
    BJU Int. 2024 Mar 22. doi: 10.1111/bju.16348.
    PubMed        

  4. HAMDY FC, Albertsen PC, Donovan JL
    Screening and active surveillance in prostate cancer: the dilemma continues.
    BJU Int. 2024 Mar 21. doi: 10.1111/bju.16345.
    PubMed        

  5. HUBER J, Karschuck P, Valdix J, Thomas C, et al
    Online decision aid for patients with prostate cancer evaluated by 11 290 patients and 91 urologists in Germany.
    BJU Int. 2024 Mar 20. doi: 10.1111/bju.16329.
    PubMed         Abstract available

  6. TAKAHASHI T
    Active surveillance in all cases of screen-detected prostate cancer.
    BJU Int. 2024 Mar 20. doi: 10.1111/bju.16344.
    PubMed        

  7. VICKERS A
    Magnetic resonance imaging-targeted prostate biopsy changed everything (so everything has to change).
    BJU Int. 2024;133:354-355.
    PubMed        

  8. MCNICHOLAS DP, Parr NJ
    Image intensifier-guided transperineal prostate biopsy for patients without a rectum: novel technique.
    BJU Int. 2024;133:487-490.
    PubMed         Abstract available

  9. JABBOUR T, Peltier A, Rocq L, Sirtaine N, et al
    Magnetic resonance imaging targeted biopsy in biopsy-naive patients and the risk of overtreatment in prostate cancer: a grading issue.
    BJU Int. 2024;133:432-441.
    PubMed         Abstract available


    BMC Cancer

  10. GUZMAN J, Weigelt K, Neumann A, Tripal P, et al
    NanoLuc Binary Technology as a methodological approach: an important new tool for studying the localization of androgen receptor and androgen receptor splice variant V7 homo and heterodimers.
    BMC Cancer. 2024;24:346.
    PubMed         Abstract available


    Br J Cancer

  11. ZHANG Y, Stopsack KH, Wu K, Song M, et al
    Multivitamin use after diagnosis and prostate cancer survival among men with nonmetastatic prostate cancer.
    Br J Cancer. 2024 Mar 15. doi: 10.1038/s41416-024-02651.
    PubMed         Abstract available


    Cancer

  12. LIM FAT G, Alibhai S
    Effect of hormonal therapies for prostate cancer on cognition: The ongoing search for clarity.
    Cancer. 2024 Mar 16. doi: 10.1002/cncr.35283.
    PubMed        


    Cancer Lett

  13. KANAOKA S, Okabe A, Kanesaka M, Rahmutulla B, et al
    Chromatin activation with H3K36me2 and compartment shift in metastatic castration-resistant prostate cancer.
    Cancer Lett. 2024;588:216815.
    PubMed         Abstract available


    Clin Cancer Res

  14. AGARWAL N, Castellano D, Alonso-Gordoa T, Arranz Arija JA, et al
    A Signal-finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration-Resistant Prostate Cancer: Results from CYCLONE 1.
    Clin Cancer Res. 2024 Mar 21. doi: 10.1158/1078-0432.CCR-23-3436.
    PubMed         Abstract available


    Eur Radiol

  15. BOELLAARD TN, van Dijk-de Haan MC, Heijmink SWTPJ, Tillier CN, et al
    Membranous urethral length measurement on preoperative MRI to predict incontinence after radical prostatectomy: a literature review towards a proposal for measurement standardization.
    Eur Radiol. 2024;34:2621-2640.
    PubMed         Abstract available


    Eur Urol

  16. VAUGIER L, Morvan C, Pasquier D, Buthaud X, et al
    Long-term Outcomes and Patterns of Relapse Following High-dose Elective Salvage Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Nodes in Prostate Cancer: OLIGOPELVIS (GETUG-P07).
    Eur Urol. 2024 Mar 14:S0302-2838(24)02131-6. doi: 10.1016/j.eururo.2024.
    PubMed         Abstract available

  17. NICKOLS NG, Tsai S, Kane N, Tran S, et al
    Systemic and Tumor-directed Therapy for Oligometastatic Prostate Cancer: The SOLAR Phase 2 Trial in De Novo Oligometastatic Prostate Cancer.
    Eur Urol. 2024 Mar 14:S0302-2838(24)00079-4. doi: 10.1016/j.eururo.2024.
    PubMed        

  18. MONTIRONI R, Cimadamore A, Giannarini G, Crestani A, et al
    Re: Outcomes of Biopsy Grade Group 1 Prostate Cancer Diagnosis in the Danish Population.
    Eur Urol. 2024 Mar 14:S0302-2838(24)02141-9. doi: 10.1016/j.eururo.2024.
    PubMed        

  19. O'CALLAGHAN M, Bulamu N, Gormly K, Jay A, et al
    Re: Prevalence of MRI Lesions in Men Responding to a GP-led Invitation for a Prostate Health Check: A Prospective Cohort Study.
    Eur Urol. 2024;85:395.
    PubMed        

  20. WEBER M, Fendler WP, Ravi Kumar AS, Calais J, et al
    Prostate-specific Membrane Antigen Positron Emission Tomography-detected Disease Extent and Overall Survival of Patients with High-risk Nonmetastatic Castration-resistant Prostate Cancer: An International Multicenter Retrospective Study.
    Eur Urol. 2024 Mar 14:S0302-2838(24)00054-X. doi: 10.1016/j.eururo.2024.
    PubMed         Abstract available

  21. MOLLER F, Mansson M, Wallstrom J, Hellstrom M, et al
    Prostate Cancers in the Prostate-specific Antigen Interval of 1.8-3 ng/ml: Results from the Goteborg-2 Prostate Cancer Screening Trial.
    Eur Urol. 2024 Mar 14:S0302-2838(24)00052-6. doi: 10.1016/j.eururo.2024.
    PubMed         Abstract available

  22. GARCIA-RUIZ A, Macarro C, Zacchi F, Morales-Barrera R, et al
    Whole-body Magnetic Resonance Imaging as a Treatment Response Biomarker in Castration-resistant Prostate Cancer with Bone Metastases: The iPROMET Clinical Trial.
    Eur Urol. 2024 Mar 14:S0302-2838(24)02133-X. doi: 10.1016/j.eururo.2024.
    PubMed        

  23. CUSSENOT O, Chambaz A, Hamdy FC
    Re: Annika Herlemann, Janet E. Cowan, Samuel L. Washington 3rd, et al. Long-term Prostate Cancer-specific Mortality After Prostatectomy, Brachytherapy, External Beam Radiation Therapy, Hormonal Therapy, or Monitoring for Localized Prostate Cancer. Eur
    Eur Urol. 2024 Mar 15:S0302-2838(24)02139-0. doi: 10.1016/j.eururo.2024.
    PubMed        

  24. BABOUDJIAN M, Diamand R, Uleri A, Beauval JB, et al
    Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions in Prostate Cancer Lead to Overtreatment?
    Eur Urol. 2024 Mar 16:S0302-2838(24)00071-X. doi: 10.1016/j.eururo.2024.
    PubMed         Abstract available

  25. NIKITAS J, Rettig M, Shen J, Reiter R, et al
    Systemic and Tumor-directed Therapy for Oligorecurrent Metastatic Prostate Cancer (SATURN): Primary Endpoint Results from a Phase 2 Clinical Trial.
    Eur Urol. 2024 Mar 16:S0302-2838(24)00058-7. doi: 10.1016/j.eururo.2024.
    PubMed         Abstract available


    Int J Radiat Oncol Biol Phys

  26. LEE K, Lall R, Chopra S, Evans MJ, et al
    SENTRI: Single-Particle Energy Transducer for Radionuclide Injections for Personalized Targeted Radionuclide Cancer Therapy.
    Int J Radiat Oncol Biol Phys. 2024;118:1575-1584.
    PubMed         Abstract available

  27. MERCIER C, Billiet C, Ost P, Joye I, et al
    Long-Term Results of a Phase 1 Dose Escalation Trial of Ablative Stereotactic Body Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2024;118:1490-1496.
    PubMed         Abstract available

  28. BAKER S, Lechner L, Liu M, Chang JS, et al
    Upfront Versus Delayed Systemic Therapy in Patients With Oligometastatic Cancer Treated With SABR in the Phase 2 SABR-5 Trial.
    Int J Radiat Oncol Biol Phys. 2024;118:1497-1506.
    PubMed         Abstract available

  29. YASAR B, Suh YE, Chapman E, Nicholls L, et al
    Simultaneous focal boost with stereotactic radiotherapy for localised intermediate to high-risk prostate cancer: Primary outcomes of the SPARC phase II trial.
    Int J Radiat Oncol Biol Phys. 2024 Mar 16:S0360-3016(24)00425.
    PubMed         Abstract available


    J Clin Oncol

  30. YU JB, DeStephano DM, Jeffers B, Horowitz DP, et al
    Updated Analysis of Comparative Toxicity of Proton and Photon Radiation for Prostate Cancer.
    J Clin Oncol. 2024 Mar 20:JCO2301604. doi: 10.1200/JCO.23.01604.
    PubMed         Abstract available


    J Urol

  31. HUSSAIN J, Sanchez-Salas R
    Letter: Point of View: What Are We Doing? The Incredible Expense and Uncertain Value of Localized Prostate Cancer Diagnostic and Therapeutic "Advances".
    J Urol. 2024 May 19:101097JU0000000000003924. doi: 10.1097/JU.0000000000003924.
    PubMed        


    PLoS One

  32. SHAHROKHI NEJAD S, Golzari Z, Zangiabadian M, Salehi Amniyeh Khozani AA, et al
    The association between zinc and prostate cancer development: A systematic review and meta-analysis.
    PLoS One. 2024;19:e0299398.
    PubMed         Abstract available

  33. PINKEOVA A, Tomikova A, Bertokova A, Fabinyova E, et al
    Glycoprofiling of proteins as prostate cancer biomarkers: A multinational population study.
    PLoS One. 2024;19:e0300430.
    PubMed         Abstract available


    Prostate

  34. HEERS H, Chwilka O, Huber J, Vogelmeier C, et al
    VOC-based detection of prostate cancer using an electronic nose and ion mobility spectrometry: A novel urine-based approach.
    Prostate. 2024 Mar 18. doi: 10.1002/pros.24692.
    PubMed         Abstract available

  35. DI BELLO F, Baudo A, de Angelis M, Jannello LMI, et al
    Other-cause mortality in incidental prostate cancer.
    Prostate. 2024 Mar 20. doi: 10.1002/pros.24689.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.